NICE is seeking public comment on the updated draft guidances through March 27, with plans to issue final draft guidances in July.

NICE has upheld its decision not to recommend Alzheimer's treatments donanemab and lecanemab for NHS use, citing high costs ...

Systematic fraud -- led by a "cabal of self-interested researchers, government accomplices, and corporate greed" in the words ...

Researchers there were conducting part of a nationwide clinical trial of Leqembi, then known by its generic name, lecanemab. The drug was the latest in a series of medications designed to clear ...

Lecanemab and donanemab can help patients live independently Alzheimer's disease is a degenerative brain disorder affecting memory The two drugs can help patients stay independent by 10-13 months Two ...

Following CHMP's reaffirmation, after having considered the additional information requested by the European Commission (EC), the EC will resume the decision-making process for lecanemab's ...

Over the course of the sit-down, which ran from Monday through Thursday, the CHMP recommended four new drugs for approval, teed up another 16 potential label expansions and—in a major win for ...

have moved closer to obtaining marketing authorization in the European Union for their Alzheimer's treatment, lecanemab, as the European Medicines Agency's Committee for Medicinal Products for ...

Following CHMP’s reaffirmation, after having considered the additional information requested by the European Commission, the EC will resume the decision-making process for lecanemab’s ...

Alzheimer's disease (AD), the most common cause of dementia, is a progressive neurodegenerative disorder affecting millions of people worldwide. AD has a multifactorial origin, resulting from an ...